291 related articles for article (PubMed ID: 15543614)
1. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Habib FK; Ross M; Ho CK; Lyons V; Chapman K
Int J Cancer; 2005 Mar; 114(2):190-4. PubMed ID: 15543614
[TBL] [Abstract][Full Text] [Related]
2. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
Bayne CW; Donnelly F; Ross M; Habib FK
Prostate; 1999 Sep; 40(4):232-41. PubMed ID: 10420151
[TBL] [Abstract][Full Text] [Related]
3. Effect of permixon on human prostate cell growth: lack of apoptotic action.
Hill B; Kyprianou N
Prostate; 2004 Sep; 61(1):73-80. PubMed ID: 15287095
[TBL] [Abstract][Full Text] [Related]
4. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers.
Strauch G; Perles P; Vergult G; Gabriel M; Gibelin B; Cummings S; Malbecq W; Malice MP
Eur Urol; 1994; 26(3):247-52. PubMed ID: 7805711
[TBL] [Abstract][Full Text] [Related]
5. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the DHT-induced PSA secretion by Verbascum xanthophoeniceum and Serenoa repens extracts in human LNCaP prostate epithelial cells.
Marcoccia D; Georgiev MI; Alipieva KI; Lorenzetti S
J Ethnopharmacol; 2014 Aug; 155(1):616-25. PubMed ID: 24928827
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
[TBL] [Abstract][Full Text] [Related]
9. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells.
Scaglione F; Lucini V; Pannacci M; Caronno A; Leone C
Pharmacology; 2008; 82(4):270-5. PubMed ID: 18849646
[TBL] [Abstract][Full Text] [Related]
11. Preventing diseases of the prostate in the elderly using hormones and nutriceuticals.
Comhaire F; Mahmoud A
Aging Male; 2004 Jun; 7(2):155-69. PubMed ID: 15672940
[TBL] [Abstract][Full Text] [Related]
12. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
[TBL] [Abstract][Full Text] [Related]
13. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
15. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia.
Buonocore D; Verri M; Cattaneo L; Arnica S; Ghitti M; Dossena M
Arch Ital Urol Androl; 2018 Sep; 90(3):199-202. PubMed ID: 30362688
[TBL] [Abstract][Full Text] [Related]
16. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate.
Bayne CW; Ross M; Donnelly F; Habib FK
J Urol; 2000 Sep; 164(3 Pt 1):876-81. PubMed ID: 10953171
[TBL] [Abstract][Full Text] [Related]
17. Hexanic Extract of Serenoa repens (Permixon
Blair HA
Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
[TBL] [Abstract][Full Text] [Related]
18. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL; Brogden RN
Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]